8.4 MNS System
Key Takeaways
- GYPA carries M and N; GYPB carries S, s, and U.
- Anti-M is often naturally occurring IgM and is not honored unless it reacts at 37 °C / AHG; anti-N is rare.
- Anti-S, anti-s, and anti-U are IgG and clinically significant.
- U-negative red cells are almost exclusively S−s− in African ancestry because of a GYPB deletion.
- Enzymes destroy M and N, have a variable effect on S and s, and leave U intact; other MNS variants such as GP.Mur exist at BB level as named hybrids, not a catalog you must recite.
8.4 MNS System
Quick Answer: GYPA encodes glycophorin A and carries M and N. GYPB encodes glycophorin B and carries S, s, and U. Anti-M is often naturally occurring IgM, cold, and not clinically significant unless it reacts at 37 °C / AHG. Anti-N is rare. Anti-S, anti-s, and anti-U are IgG and clinically significant. U-negative red cells are almost only S−s− cells in African ancestry (GYPB deletion). Enzymes destroy M and N, have a variable effect on S and s, and leave U resistant. Dosage is common. GPA/GPB hybrids such as GP.Mur exist; at BB level you need to know that other MNS variants exist, not the whole Miltenberger catalog.
MNS is II.B.4 on the June 9, 2026 outline. The exam splits the system in half: treat M and N like Lewis-style nuisance antibodies until they prove they can live at 37 °C, and treat S, s, and U like Duffy or Kidd.
Two genes, two proteins, five everyday antigens
GYPA and GYPB sit next to each other and are homologous, which is why they recombine into hybrids. You do not need the nucleotide map. You do need the antigen addresses:
| Gene | Protein | Antigens | Enzyme effect |
|---|---|---|---|
| GYPA | Glycophorin A | M, N | Destroyed by ficin/papain |
| GYPB | Glycophorin B | S, s, U | S/s variable; U resistant |
M versus N is amino acids 1 and 5 of GPA (M = Ser1/Gly5; N = Leu1/Glu5). The N-terminus of GPB looks like N, so almost everyone has a little N-like structure even if they type N− on GPA — one reason anti-N is uncommon in N− people. S versus s is Met29 versus Thr29 on GPB. U is a high-prevalence antigen on GPB near the membrane. If GPB is missing, S, s, and U go with it.
Approximate antigen-positive frequencies used on BB items:
| Antigen | European ancestry | African ancestry |
|---|---|---|
| M | ~78% | ~74% |
| N | ~72% | ~75% |
| S | ~55% | ~31% |
| s | ~89% | ~97% |
| U | ~100% | ~99% |
U-negative is almost never a European-ancestry type. It is found in people of African ancestry who are S−s− because of a GYPB deletion (or a GYPB rearrangement that removes the U epitope). Some S−s− cells are U+var (weak U) rather than true U−; those people may still make anti-U. For unit selection, a patient with anti-U needs U− red cells from a rare-donor file, and those units will type S−s−.
Dosage is the everyday MNS serologic trap. Anti-M, anti-N, anti-S, and anti-s often react more strongly with homozygous cells (M+N−, S+s−, and so on) than with heterozygotes. Rule them out on a double-dose cell, the same way you rule out Kidd and Duffy.
Antibody rules: M/N versus S/s/U
Anti-M is the common MNS antibody and the one candidates over-honor. It is often naturally occurring, IgM, strongest at 4 °C or room temperature, shows dosage, and may be pH-dependent (some reagents pick it up better in a slightly acid environment). If anti-M is nonreactive at 37 °C and at AHG, it is not clinically significant. Issue units that are compatible at 37 °C / IAT. You do not routinely search for M− inventory. If the same antibody reacts at 37 °C or in the AHG phase (some anti-M has an IgG component), it graduates and you honor it with M− red cells. That is the same 37 °C gate you already used for anti-A1 and for Lewis.
Anti-N is rare. When it appears it is usually a cold IgM and not significant. A notable exception the exam may whisper is anti-N-like antibody in dialysis patients historically exposed to formaldehyde-sterilized dialyzers — a curiosity, not a reason to treat every anti-N like anti-K.
Anti-S, anti-s, and anti-U are IgG, 37 °C / AHG, and clinically significant. They cause HTR and HDFN. Honor them. Anti-U in particular can be severe, and U− units are scarce. Do not manage anti-U with the anti-M playbook.
Enzyme patterns are how you sort the family on a panel:
- M and N destroyed by ficin and papain. A cold antibody that vanishes with enzymes and shows M dosage is anti-M, not anti-I and not anti-P1 (those are enzyme-enhanced).
- S and s are variable. Some enzyme methods weaken or destroy them; some leave residual reactivity. Do not use a single enzyme result as the only proof of anti-S.
- U is resistant. An antibody that still reacts with enzyme-treated S−s−U+ cells, or that reacts with all cells except S−s−U− cells after enzymes, is in U (or another enzyme-resistant high-prevalence) territory, not anti-M.
- DTT does not destroy MNS antigens. DTT is still the Kell reagent.
Hybrids: know that they exist
Because GYPA and GYPB are homologous and adjacent, unequal crossing-over produces GPA/GPB hybrid proteins. The teaching name at BB level is that other MNS variants exist. GP.Mur (Mi.III) is the example worth one sentence: it is relatively common in some Southeast Asian populations, carries low-frequency MNS (Miltenberger) antigens, and can make a panel cell react when every common MNS specificity has been ruled out. You are not required to recite the entire Miltenberger series. You are required not to say that M, N, S, s, and U are the only antigens the system can present.
If a stem hands you an unexplained extra reaction on an Asian-ancestry panel cell after M, N, S, s, and U look excluded, the answer space is an MNS hybrid (for example GP.Mur), not a new ABO subgroup and not McLeod.
Four-system comparison you must be able to rebuild from memory
This is the II.B.4 / II.B.7 / II.B.8 / II.B.9 synthesis table. If you can fill it on scrap paper, you can finish most blood-group antibody items in this chapter.
| Feature | Kell (II.B.7) | Duffy (II.B.9) | Kidd (II.B.8) | MNS (II.B.4) |
|---|---|---|---|---|
| Typical Ig class | IgG | IgG | IgG | M/N often IgM; S/s/U IgG |
| Enzymes (ficin/papain) | Resistant (not destroyed) | Fya/Fyb destroyed; Fy3 resistant | Enhanced | M/N destroyed; S/s variable; U resistant |
| DTT / AET | Destroyed | Resistant | Resistant | Resistant |
| Clinical significance | Always | Yes | Always | M/N only if 37 °C / AHG; S/s/U always |
| HDFN | Can be severe (erythroid suppression) | Yes, usually less severe than Kell | Usually mild | S/s/U yes; M rarely |
| Notable trap | DTT vs Kidd; McLeod ≠ Ko; K second to D | GATA Fy(a−b−) is not a true null; do not invent anti-Fyb | Evanescent; honor historical anti-Jka | Do not honor RT-only anti-M; U− ≈ S−s− African GYPB deletion |
Read the table by column when the stem names the system, and by row when the stem names a technique. Enzyme-destroyed plus AHG-significant is Duffy or S/s, not Kell or Kidd. Enzyme-enhanced plus a delayed HTR is Kidd. DTT-destroyed is Kell until proven otherwise. A cold IgM that enzymes destroy is anti-M until it proves it can live at 37 °C.
Exam traps
- Honoring every anti-M the way you honor anti-K. Room-temperature-only anti-M is not routinely honored.
- Calling a U− type a random European finding. U− is almost only S−s− African ancestry (GYPB deletion).
- Expecting enzymes to destroy U, or to enhance M and N like Kidd.
- Using DTT to confirm an MNS antibody. DTT is the Kell destroyer.
- Ruling out anti-S on a single heterozygous S+s+ cell. Dosage applies here too.
- Pretending MNS has only five antigens and no hybrids. GP.Mur and other variants exist.
- Mixing the four-system enzyme row: Kell stays, Duffy Fya/Fyb die, Kidd gets stronger, M/N die.
Anti-M reacts 3+ at immediate spin / room temperature, is negative at 37 °C, and the IAT is negative. What is the appropriate red-cell selection?
U-negative red cells are found almost exclusively in which group?
Which enzyme pattern is correct for the MNS system?